973 related articles for article (PubMed ID: 16251317)
21. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
[TBL] [Abstract][Full Text] [Related]
22. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
23. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
25. Maraviroc: pharmacokinetics and drug interactions.
Abel S; Back DJ; Vourvahis M
Antivir Ther; 2009; 14(5):607-18. PubMed ID: 19704163
[TBL] [Abstract][Full Text] [Related]
26. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Bredeek UF; Harbour MJ
Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
28. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
[TBL] [Abstract][Full Text] [Related]
29. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
[TBL] [Abstract][Full Text] [Related]
30. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
[TBL] [Abstract][Full Text] [Related]
31. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
32. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
[TBL] [Abstract][Full Text] [Related]
33. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
34. Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.
Yoshimura K; Harada S; Boonchawalit S; Kawanami Y; Matsushita S
J Gen Virol; 2014 Aug; 95(Pt 8):1816-1826. PubMed ID: 24795449
[TBL] [Abstract][Full Text] [Related]
35. Treatment of HIV infection with the CCR5 antagonist maraviroc.
Kromdijk W; Huitema AD; Mulder JW
Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
[TBL] [Abstract][Full Text] [Related]
36. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
Flynn JK; Paukovics G; Moore MS; Ellett A; Gray LR; Duncan R; Salimi H; Jubb B; Westby M; Purcell DF; Lewin SR; Lee B; Churchill MJ; Gorry PR; Roche M
Virology; 2013 Jul; 442(1):51-8. PubMed ID: 23602007
[TBL] [Abstract][Full Text] [Related]
37. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
[TBL] [Abstract][Full Text] [Related]
38. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
Strizki JM; Tremblay C; Xu S; Wojcik L; Wagner N; Gonsiorek W; Hipkin RW; Chou CC; Pugliese-Sivo C; Xiao Y; Tagat JR; Cox K; Priestley T; Sorota S; Huang W; Hirsch M; Reyes GR; Baroudy BM
Antimicrob Agents Chemother; 2005 Dec; 49(12):4911-9. PubMed ID: 16304152
[TBL] [Abstract][Full Text] [Related]
39. Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
[TBL] [Abstract][Full Text] [Related]
40. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
